Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus

Prog Cardiovasc Dis. May-Jun 2020;63(3):383-385. doi: 10.1016/j.pcad.2020.02.007. Epub 2020 Feb 12.
No abstract available

MeSH terms

  • Animals
  • Antioxidants / therapeutic use
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects*
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / virology
  • Dietary Supplements* / adverse effects
  • Enzyme Inhibitors / therapeutic use
  • Host Microbial Interactions
  • Humans
  • Hydrogen Peroxide / metabolism
  • Immunologic Factors / therapeutic use
  • Influenza, Human / drug therapy*
  • Influenza, Human / immunology
  • Influenza, Human / virology
  • Interferon Type I / immunology
  • Interferon Type I / metabolism*
  • NADPH Oxidase 2 / antagonists & inhibitors
  • NADPH Oxidase 2 / metabolism
  • Orthomyxoviridae / drug effects*
  • Orthomyxoviridae / immunology
  • Orthomyxoviridae / pathogenicity
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / virology
  • Toll-Like Receptor 7 / metabolism
  • Virulence

Substances

  • Antioxidants
  • Antiviral Agents
  • Enzyme Inhibitors
  • Immunologic Factors
  • Interferon Type I
  • TLR7 protein, human
  • Toll-Like Receptor 7
  • Hydrogen Peroxide
  • CYBB protein, human
  • NADPH Oxidase 2

Supplementary concepts

  • COVID-19
  • COVID-19 drug treatment
  • severe acute respiratory syndrome coronavirus 2